|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||32.95 - 33.45|
|52 Week Range||29.83 - 35.38|
|PE Ratio (TTM)||27.74|
|Dividend & Yield||1.28 (3.84%)|
|1y Target Est||N/A|
Top Analyst Reports for Pfizer, TJX Companies & Honda
The Food and Drug Administration has approved a new medicine for use against a rare, rapidly progressing blood cancer after other treatments have failed. The agency approved Pfizer Inc.'s Besponsa for ...
The U.S. Food and Drug Administration (FDA) said on Thursday it approved Pfizer Inc's rare blood cancer drug, Besponsa, with a boxed warning. Besponsa was approved to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).